← All trials
NCT04378647
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2020
- Primary completion
- Aug 30, 2026
- Completion date
- Aug 30, 2026
- First posted
- May 7, 2020
- Last posted
- May 11, 2020
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaLead sponsor
- Institut Català d'Oncologia, Hospital Duran i ReynalsOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.